Your session is about to expire
← Back to Search
GDC-1971 + Atezolizumab for Advanced Solid Cancers
Study Summary
This trial will study the safety and efficacy of GDC-1971 in combination with atezolizumab in people with locally advanced or metastatic solid tumors. There will be two stages to the trial- a dose-finding stage and an expansion stage. In the expansion stage, participants with NSCLC PD-L1 high, NSCLC PD-L1 low, HNSCC PD-L1 positive, BRAF WT melanoma, and any other locally advanced or metastatic solid tumors will be enrolled.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My head or neck cancer is PD-L1 positive and has returned or spread, with no prior treatments.My high blood pressure is not under control.My organs are working well.My heart's pumping ability is below normal or less than 50%.My advanced cancer has not responded to or I cannot tolerate standard treatments.My advanced cancer has not improved after standard treatment or I cannot tolerate it.I have brain metastases that are untreated or getting worse.I have an autoimmune disease but it's either thyroid issues treated with hormones or controlled Type I diabetes.I am fully active or can carry out light work.I have a significant history of liver problems, including hepatitis, alcohol abuse, or cirrhosis.My advanced lung cancer is PD-L1 positive and lacks EGFR and ALK mutations.My cancer has spread to the lining of my brain and spinal cord.My melanoma is advanced, not removable by surgery, and has worsened after anti PD1/PD-L1 therapy.
- Group 1: Expansion Stage: GDC-1971
- Group 2: Dose-finding Stage: GDC-1971
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the upper-limit for enrollment in this experiment?
"Affirmative. As indicated by data hosted on clinicaltrials.gov, this research trial is actively seeking out new participants with a goal of 232 patients from 3 separate medical facilities. The original posting date was August 17th 2022 and the latest update took place November 22nd 2022."
Has the FDA endorsed GDC-1971 for use?
"The safety of GDC-1971 has been assessed at 1 due to the limited evidence associated with its efficacy and security, as it is still in Phase 1."
Is registration available for this clinical investigation?
"Affirmative. Per clinicaltrials.gov, recruitment for this trial is in progress and has been since August 17th 2022. Last updated on November 22nd 2022, the study requires 232 patients to be enrolled across 3 sites."
Share this study with friends
Copy Link
Messenger